Cargando…
Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of cancer death among men and women in North America. More than half of all patients diagnosed with lung cancer are diagnosed with advanced disease. Most cases of lung cancer are non-small cell lung cancer (NSCLC). Erlo...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2006
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437913/ https://www.ncbi.nlm.nih.gov/pubmed/16925455 http://dx.doi.org/10.18553/jmcp.2006.12.6.472 |